Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Lyra Therapeutics ( (LYRA) ) is now available.
On March 31, 2026, Lyra Therapeutics, Inc. agreed to terminate its lease for 22,343 rentable square feet at 480 Arsenal Way in Watertown, Massachusetts, which had been scheduled to run until April 30, 2027. The lease will now end no later than May 31, 2026, with rent obligations having ceased on January 31, 2026, and the company forfeiting a $302,514.84 security deposit and paying a $1 million lease modification fee, with potential additional payment tied to any future sale transaction.
On April 7, 2026, the company also entered into a lease termination agreement for 28,858 rentable square feet at 880 Winter Street in Waltham, Massachusetts, originally set to expire on June 30, 2033. That lease will now terminate on May 31, 2026, with Lyra forfeiting a $1,089,389 security deposit and paying a $1.5 million termination fee as liquidated damages, ending rent obligations as of March 31, 2026, and securing mutual releases, which together reflect a strategic downsizing or consolidation of its physical footprint.
The most recent analyst rating on (LYRA) stock is a Sell with a $0.46 price target. To see the full list of analyst forecasts on Lyra Therapeutics stock, see the LYRA Stock Forecast page.
Spark’s Take on LYRA Stock
According to Spark, TipRanks’ AI Analyst, LYRA is a Underperform.
The score is driven down primarily by weak financials (minimal revenue, losses, cash burn, and negative equity) and very bearish technicals. Significant negative corporate events (delisting risk and halted operations) add further pressure, while valuation signals provide limited offset given ongoing losses and no dividend.
To see Spark’s full report on LYRA stock, click here.
More about Lyra Therapeutics
Lyra Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies, including drug-device combinations, for ear, nose, and throat diseases. The company maintains research and office facilities in the Greater Boston area to support its clinical and operational activities in the life sciences sector.
Average Trading Volume: 98,868
Technical Sentiment Signal: Sell
Current Market Cap: $940.7K
For an in-depth examination of LYRA stock, go to TipRanks’ Overview page.